{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:01Z","timestamp":1790878321827,"version":"4.1.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Neoadjuvant chemoradiation (NCRT) followed by surgical resection represents a standard approach for patients with locally advanced esophageal\/gastroesophageal junction (GEJ) cancers. Sotigalimab is a high-affinity CD40 agonist antibody capable of inducing and expanding antitumor immune responses by activating dendritic cells, T and B lymphocytes, NK cells, and M1 macrophages. This study examined the safety and efficacy of combining sotigalimab with NCRT in patients with esophageal or GEJ cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with resectable (T1-3 Nx) adenocarcinoma or squamous cell carcinoma of the esophagus or GEJ were eligible. T1N0 and cervical tumors were excluded. Study treatment: weekly carboplatin\/paclitaxel with concurrent radiation 5,040 cGy plus 3 to 4 doses of sotigalimab prior to Ivor Lewis esophagectomy. Primary efficacy endpoint was the pathologic complete response (path CR) rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-three patients were enrolled (adenocarcinoma 76%, squamous cell carcinoma 24%; and clinical stage III 67%). Ninety percent of patients received all planned doses of sotigalimab. The most common adverse events attributed to sotigalimab were nausea, fever\/chills, fatigue, and cytokine release syndrome; most of these were grade 1 to 2. Grade \u22653 cytokine release syndrome was observed in 3 patients (9%). Twenty-five of the 29 efficacy-evaluable patients underwent an R0 resection (87.9%), with an overall path CR rate of 37.9% (11\/29). Post-tumor samples demonstrated increased infiltration and activation of dendritic cells, monocytes, and cytotoxic T cells compared with baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Sotigalimab combined with NCRT for esophageal or GEJ cancers was generally well tolerated and achieved path CR rates that compare favorably with historical data and are promising for this treatment strategy. Clinical trial information: NCT03165994.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The current study represents the first report to evaluate a CD40 agonist antibody in combination with concurrent chemoradiation in the neoadjuvant setting for patients with esophageal\/GEJ cancers. This novel strategy was both safe and feasible, producing encouraging path CR rates that compare favorably with historical data. Our findings support the further evaluation of how immune-based therapies may be incorporated into perioperative treatment paradigms for upper gastrointestinal malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0513","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:15:26Z","timestamp":1738732526000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-1753","authenticated-orcid":false,"given":"Andrew H.","family":"Ko","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-504X","authenticated-orcid":false,"given":"Joseph","family":"Chao","sequence":"additional","affiliation":[{"name":"2City of Hope Comprehensive Cancer Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-6950","authenticated-orcid":false,"given":"Marcus S.","family":"Noel","sequence":"additional","affiliation":[{"name":"3Georgetown University Hospital, Washington, District of Columbia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-6140","authenticated-orcid":false,"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[{"name":"4University of Washington School of Medicine, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-8403","authenticated-orcid":false,"given":"Davendra","family":"Sohal","sequence":"additional","affiliation":[{"name":"5University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9888-0861","authenticated-orcid":false,"given":"Mary","family":"Crow","sequence":"additional","affiliation":[{"name":"6Renovatio Clinical, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-6004","authenticated-orcid":false,"given":"Paul E.","family":"Oberstein","sequence":"additional","affiliation":[{"name":"7Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-3072","authenticated-orcid":false,"given":"Aaron J.","family":"Scott","sequence":"additional","affiliation":[{"name":"8University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9153-2006","authenticated-orcid":false,"given":"Autumn J.","family":"McRee","sequence":"additional","affiliation":[{"name":"9University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4681-1705","authenticated-orcid":false,"given":"Caio Max Sao Pedro","family":"Rocha Lima","sequence":"additional","affiliation":[{"name":"10Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6428-428X","authenticated-orcid":false,"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-489X","authenticated-orcid":false,"given":"Bridget P.","family":"Keenan","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8894","authenticated-orcid":false,"given":"Maira","family":"Soto","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-9030","authenticated-orcid":false,"given":"Erin L.","family":"Filbert","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4156-2995","authenticated-orcid":false,"given":"Frank J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3635-8094","authenticated-orcid":false,"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"2025022112055366300_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025022112055366300_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroent"},{"key":"2025022112055366300_bib3","doi-asserted-by":"crossref","first-page":"102486","DOI":"10.1016\/j.canep.2023.102486","article-title":"Global trends in esophageal cancer mortality with predictions to 2025, and in incidence by histotype","volume":"87","author":"Santucci","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"2025022112055366300_bib4","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2025022112055366300_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"2025022112055366300_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2025022112055366300_bib7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025022112055366300_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025022112055366300_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025022112055366300_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"2025022112055366300_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"21","author":"Enell Smith","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2025022112055366300_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00262-020-02814-2","article-title":"APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application","volume":"70","author":"Filbert","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"Suppl 15","key":"2025022112055366300_bib13","doi-asserted-by":"crossref","first-page":"TPS3110","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3110","article-title":"Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors","volume":"34","author":"Bendell","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025022112055366300_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025022112055366300_bib15","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","article-title":"A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1\/PD-L1","volume":"27","author":"Weiss","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025022112055366300_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025022112055366300_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2767-9764.CRC-23-0550","article-title":"Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal\/gastroesophageal junction cancer","volume":"4","author":"Soto","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025022112055366300_bib18","first-page":"5889","article-title":"Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice","volume":"18","author":"Ahn","year":"2019","journal-title":"Oncol Lett"},{"key":"2025022112055366300_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","article-title":"A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2025022112055366300_bib20","doi-asserted-by":"crossref","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025022112055366300_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-021-01442-3","article-title":"Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy","volume":"20","author":"Yan","year":"2021","journal-title":"Mol Cancer"},{"key":"2025022112055366300_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12885-023-10650-7","article-title":"Spatial characterization and quantification of CD40 expression across cancer types","volume":"23","author":"Bates","year":"2023","journal-title":"BMC Cancer"},{"key":"2025022112055366300_bib23","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.21873\/anticanres.10991","article-title":"CD40 expression in human esophageal squamous cell carcinoma is associated with tumor progression and lymph node metastasis","volume":"36","author":"Matsumura","year":"2016","journal-title":"Anticancer Res"},{"key":"2025022112055366300_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/PPO.0000000000000181","article-title":"Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy: going beyond local control","volume":"22","author":"Schoenhals","year":"2016","journal-title":"Cancer J"},{"key":"2025022112055366300_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025022112055366300_bib26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025022112055366300_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"2025022112055366300_bib28","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"Van Den Ende","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025022112055366300_bib29","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1158\/1078-0432.CCR-22-0413","article-title":"Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2025022112055366300_bib30","first-page":"S852","article-title":"Addition of durvalumab to CROSS in esophageal adenocarcinoma is feasible and safe (abstract 1521P)","volume":"34","author":"Schlosser","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 16","key":"2025022112055366300_bib31","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2024.42.16_suppl.4000","article-title":"A phase II\/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)","volume":"42","author":"Eads","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025022112055366300_bib32","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","article-title":"Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer","volume":"78","author":"Rech","year":"2018","journal-title":"Cancer Res"},{"key":"2025022112055366300_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 17","key":"2025022112055366300_bib34","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1","article-title":"Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)","volume":"42","author":"Hoeppner","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0513\/3538996\/crc-24-0513.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/349\/3545622\/crc-24-0513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/349\/3545622\/crc-24-0513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:06:15Z","timestamp":1740121575000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/2\/349\/752039\/A-Phase-2-Study-of-Sotigalimab-a-CD40-Agonist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0513","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7683940","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28457881","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28457872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28457884","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28457875","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28457878","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28457869","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}